Deep learning-enabled fully automated pipeline system for segmentation and classification of single-mass breast lesions using contrast-enhanced mammography: a prospective, multicentre study.
Breast lesions
Classification
Contrast-enhanced mammography
Deep learning
Full automated pipeline system
Segmentation
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
08
12
2022
revised:
01
03
2023
accepted:
02
03
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Breast cancer is the leading cause of cancer-related deaths in women. However, accurate diagnosis of breast cancer using medical images heavily relies on the experience of radiologists. This study aimed to develop an artificial intelligence model that diagnosed single-mass breast lesions on contrast-enhanced mammography (CEM) for assisting the diagnostic workflow. A total of 1912 women with single-mass breast lesions on CEM images before biopsy or surgery were included from June 2017 to October 2022 at three centres in China. Samples were divided into training and validation sets, internal testing set, pooled external testing set, and prospective testing set. A fully automated pipeline system (FAPS) using RefineNet and the Xception + Pyramid pooling module (PPM) was developed to perform the segmentation and classification of breast lesions. The performances of six radiologists and adjustments in Breast Imaging Reporting and Data System (BI-RADS) category 4 under the FAPS-assisted strategy were explored in pooled external and prospective testing sets. The segmentation performance was assessed using the Dice similarity coefficient (DSC), and the classification was assessed using heatmaps, area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. The radiologists' reading time was recorded for comparison with the FAPS. This trial is registered with China Clinical Trial Registration Centre (ChiCTR2200063444). The FAPS-based segmentation task achieved DSCs of 0.888 ± 0.101, 0.820 ± 0.148 and 0.837 ± 0.132 in the internal, pooled external and prospective testing sets, respectively. For the classification task, the FAPS achieved AUCs of 0.947 (95% confidence interval [CI]: 0.916-0.978), 0.940 (95% [CI]: 0.894-0.987) and 0.891 (95% [CI]: 0.816-0.945). It outperformed radiologists in terms of classification efficiency based on single lesions (6 s vs 3 min). Moreover, the FAPS-assisted strategy improved the performance of radiologists. BI-RADS category 4 in 12.4% and 13.3% of patients was adjusted in two testing sets with the assistance of FAPS, which may play an important guiding role in the selection of clinical management strategies. The FAPS based on CEM demonstrated the potential for the segmentation and classification of breast lesions, and had good generalisation ability and clinical applicability. This study was supported by the Taishan Scholar Foundation of Shandong Province of China (tsqn202211378), National Natural Science Foundation of China (82001775), Natural Science Foundation of Shandong Province of China (ZR2021MH120), and Special Fund for Breast Disease Research of Shandong Medical Association (YXH2021ZX055).
Sections du résumé
Background
UNASSIGNED
Breast cancer is the leading cause of cancer-related deaths in women. However, accurate diagnosis of breast cancer using medical images heavily relies on the experience of radiologists. This study aimed to develop an artificial intelligence model that diagnosed single-mass breast lesions on contrast-enhanced mammography (CEM) for assisting the diagnostic workflow.
Methods
UNASSIGNED
A total of 1912 women with single-mass breast lesions on CEM images before biopsy or surgery were included from June 2017 to October 2022 at three centres in China. Samples were divided into training and validation sets, internal testing set, pooled external testing set, and prospective testing set. A fully automated pipeline system (FAPS) using RefineNet and the Xception + Pyramid pooling module (PPM) was developed to perform the segmentation and classification of breast lesions. The performances of six radiologists and adjustments in Breast Imaging Reporting and Data System (BI-RADS) category 4 under the FAPS-assisted strategy were explored in pooled external and prospective testing sets. The segmentation performance was assessed using the Dice similarity coefficient (DSC), and the classification was assessed using heatmaps, area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. The radiologists' reading time was recorded for comparison with the FAPS. This trial is registered with China Clinical Trial Registration Centre (ChiCTR2200063444).
Findings
UNASSIGNED
The FAPS-based segmentation task achieved DSCs of 0.888 ± 0.101, 0.820 ± 0.148 and 0.837 ± 0.132 in the internal, pooled external and prospective testing sets, respectively. For the classification task, the FAPS achieved AUCs of 0.947 (95% confidence interval [CI]: 0.916-0.978), 0.940 (95% [CI]: 0.894-0.987) and 0.891 (95% [CI]: 0.816-0.945). It outperformed radiologists in terms of classification efficiency based on single lesions (6 s vs 3 min). Moreover, the FAPS-assisted strategy improved the performance of radiologists. BI-RADS category 4 in 12.4% and 13.3% of patients was adjusted in two testing sets with the assistance of FAPS, which may play an important guiding role in the selection of clinical management strategies.
Interpretation
UNASSIGNED
The FAPS based on CEM demonstrated the potential for the segmentation and classification of breast lesions, and had good generalisation ability and clinical applicability.
Funding
UNASSIGNED
This study was supported by the Taishan Scholar Foundation of Shandong Province of China (tsqn202211378), National Natural Science Foundation of China (82001775), Natural Science Foundation of Shandong Province of China (ZR2021MH120), and Special Fund for Breast Disease Research of Shandong Medical Association (YXH2021ZX055).
Identifiants
pubmed: 36969336
doi: 10.1016/j.eclinm.2023.101913
pii: S2589-5370(23)00090-1
pmc: PMC10034267
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101913Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
HX received funding from 10.13039/501100007129Natural Science Foundation of Shandong Province of China (ZR2021MH120). NM received funding from Taishan Scholar Foundation of Shandong Province of China (tsqn202211378), 10.13039/501100001809National Natural Science Foundation of China (82001775), and Special Fund for Breast Disease Research of Shandong Medical Association (YXH2021ZX055). All other authors declare no competing interests.
Références
Nat Commun. 2021 Sep 24;12(1):5645
pubmed: 34561440
Int J Comput Assist Radiol Surg. 2021 Jun;16(6):979-988
pubmed: 33966155
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Imaging. 2021 Jan;69:269-279
pubmed: 33032103
Med Phys. 2022 Feb;49(2):966-977
pubmed: 34860417
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
JAMA. 2014 Apr 2;311(13):1327-35
pubmed: 24691608
Lancet Digit Health. 2020 Mar;2(3):e138-e148
pubmed: 33334578
Neuro Oncol. 2021 Feb 25;23(2):304-313
pubmed: 32706862
Nat Commun. 2021 Mar 25;12(1):1851
pubmed: 33767170
Invest Radiol. 2019 Jun;54(6):325-332
pubmed: 30652985
Theranostics. 2021 Jan 1;11(4):1982-1990
pubmed: 33408793
Radiology. 2017 Nov;285(2):389-400
pubmed: 28654337
Clin Cancer Res. 2020 Apr 15;26(8):1944-1952
pubmed: 31937619
Int J Comput Assist Radiol Surg. 2019 Feb;14(2):249-257
pubmed: 30367322
Lancet Digit Health. 2021 May;3(5):e286-e294
pubmed: 33773969
J Nucl Med. 2020 Apr;61(4):488-495
pubmed: 32060219
Nat Commun. 2021 Nov 17;12(1):6654
pubmed: 34789774
Lancet Digit Health. 2021 Apr;3(4):e250-e259
pubmed: 33766289
Radiology. 2021 Nov;301(2):398-406
pubmed: 34491126
Eur J Radiol. 2018 Jan;98:207-213
pubmed: 29279165
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4293-4306
pubmed: 34131803
J Hematol Oncol. 2021 Sep 26;14(1):154
pubmed: 34565412
Med Image Anal. 2021 Oct;73:102147
pubmed: 34246849
Radiology. 2021 Aug;300(2):438-447
pubmed: 34003056